These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2007-003976-20 A randomised, double blind, placebo and active controlled, parallel group study to evaluate the analgesic effect of a single dose of GRC 6211, a TRPV1 receptor antagonist on pain following third mo... 2008-02-25 due-trials
Reported results 2011-000107-40 A Phase IIb, 12 week Randomized, Double-Blind, Parallel Group, Placebo-Controlled study to evaluate Efficacy, Safety and Tolerability of 2, 4 and 6 mg of Revamilast in patients with Active Rheumatoid ... 2012-12-20 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-000270-57 A phase II, 12-week randomized, double-blind, triple dummy, parallel group, placebo-controlled, dose range finding study to evaluate safety, tolerability and efficacy of revamilast in patients with c... 2013-04-08 bad-data
Ongoing, reported early 2011-003147-22 A Multicenter, Open-Label, Comparator-Controlled, Parallel Group, Phase 3 Study to Assess the Efficacy and Safety of Clotrimazole/Clindamycin (200 mg/100 mg FDC) Ovules Compared with Metronidazole (50... not-yet-due
Not reported 2011-005879-16 A Phase II, 4 Week Randomized, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients with Painful Diabetic Neur... 2012-06-18 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-002320-33 A Phase 2, 4 Week Randomized, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients with Painful Diabetic Perip... 2014-07-23 bad-data
Completed, reported early 2012-002567-99 An integrated Phase I/IIa study to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of inhaled GRC 17536 in healthy adult volunteers and multiple ascending doses in pat... 2013-10-15 not-yet-due
Reported results 2013-002728-17 A Phase 2a, Multi-Centre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of Inhaled GRC 17536, Administered for 4 Weeks, in Patients w... 2014-07-30 due-trials